Stryker Corporation $SYK Shares Sold by Benjamin Edwards Inc.

Key Points

• Benjamin Edwards Inc. reduced its Stryker stake by 11.6% in the second quarter, selling 18,177 shares and retaining 138,678 shares valued at approximately $43.7 million. Institutional investors own 77.09% of SYK.
• Insiders sold 351,267 Stryker shares worth about $118.2 million during the last quarter, including Director Ronda E. Stryker’s $100.8 million sale of 300,000 shares.
• Stryker reported quarterly EPS of $3.69, above the $3.49 consensus, while revenue rose 9.4% year over year to $6.59 billion. Analysts maintain a “Moderate Buy” consensus with an average price target of $386.28, and the company declared a quarterly dividend of $0.88 per share.

Benjamin Edwards Inc. lessened its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 11.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,678 shares of the medical technology company's stock after selling 18,177 shares during the quarter. Benjamin Edwards Inc.'s holdings in Stryker were worth $43,676,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of SYK. VanderPol Investments L.L.C. lifted its holdings in Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock valued at $732,000 after acquiring an additional 28 shares during the period. KCM Investment Advisors LLC grew its stake in shares of Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock worth $653,000 after purchasing an additional 28 shares during the period. Rossby Financial LCC increased its holdings in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock valued at $159,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC increased its holdings in shares of Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock valued at $403,000 after purchasing an additional 29 shares in the last quarter. Finally, ICW Investment Advisors LLC lifted its stake in shares of Stryker by 0.6% in the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company's stock valued at $1,791,000 after purchasing an additional 30 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Dylan Bram Crotty sold 441 shares of the company's stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. UBS Group began coverage on shares of Stryker in a research report on Tuesday, July 28th. They set a "buy" rating and a $400.00 target price on the stock. Citigroup reiterated a "buy" rating on shares of Stryker in a research report on Thursday, August 13th. Wolfe Research cut Stryker from an "outperform" rating to a "peer perform" rating in a report on Thursday, August 13th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Stryker in a research note on Friday, July 31st. Finally, Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and an average target price of $386.28.

Stryker Trading Up 2.9%

Shares of SYK opened at $331.32 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The stock has a market cap of $127.08 billion, a price-to-earnings ratio of 34.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The firm has a 50 day simple moving average of $329.10 and a 200-day simple moving average of $331.47.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker's revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source